Healthcare systems must turn proven research into patient care faster with practical infrastructure, product champions, trust ...

What happened at BIO? This selected coverage from the BIO 2026 meeting in San Francisco includes highlights from panels on ...

A “Godzilla” El Niño could disrupt pharma supply chains, pushing life sciences firms toward AI-driven weather forecasting, ...

Industry Explorers Blaze On: A series of stories of longtime leaders, still active in the industry, sharing their historical perspectives on life sciences industry innovation. A consuming interest, ...

Speed alone no longer guarantees success; here’s what matters most in today’s launch environment. In today’s launch environment, order of entry (OOE) isn’t destiny. Many brands still anchor strategy ...

Since the start of his second term, President Trump has shown a clear commitment to improving access to medicines for American patients. In late September 2025, his Administration reaffirmed this ...

Emerging biotech companies are tasked with a dual mandate: advance breakthrough science to create new medicines for patients, and in doing so, create value for investors. There is no established ...

Marc Richards Biotechnology companies often offer a promise of future success, but it can take years to determine whether all the effort (and expense) will translate into returns. Because of the ...

GLP-1s didn’t just change how patients lose weight. They changed how pharma must sell. GLP-1 receptor agonists were supposed to be a diabetes treatment. Instead, they became the first pharmaceutical ...

Biotech has entered a new era of financial discipline. The days of easy capital, billion-dollar preclinical valuations, and “platform first, data later” investing have largely disappeared. Today, ...

Spinning off a $4 billion biopharma business is no easy task. Integrated functions need to be separated, governance boards created, leadership teams assembled, and corporate headquarters established.

As the fentanyl epidemic rages on, opioid antagonist rescue agents like Narcan, Kloxxado, and Opvee have become omnipresent. Like defibrillators and EpiPens, advocates insist they should be available ...